跳至主要内容
临床试验/NCT07180966
NCT07180966已完成不适用

Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation

Ruijin Hospital1 个研究点 分布在 1 个国家目标入组 780 人开始时间: 2019年1月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
780
试验地点
1
主要终点
Development of SAH Index for Risk-Adjusted Gastric Cancer Surgical Evaluation

研究概览

简要总结

This study develops the Surgical Assessment and Healthcare (SAH) Index, a new tool to fairly evaluate gastric cancer surgery outcomes. Gastric cancer is a serious disease that often requires major surgery, but it can be difficult to compare how well different hospitals or surgeons perform because patients have different levels of risk before surgery.

The SAH Index will help solve this problem by creating a standardized way to account for patient risk factors when evaluating surgical results. The study analyzes data from 780 patients who had gastric cancer surgery in 2019, looking at factors like patient age, tumor characteristics, molecular markers, and surgical outcomes.

By combining clinical information (like patient health), pathological details (like tumor type), and molecular features (like genetic markers), the SAH Index will create risk categories that allow fair comparison of surgical outcomes. This tool could help hospitals improve their care, help patients and families understand their treatment options, and help doctors make better treatment decisions.

The study uses only existing medical records and does not involve any new treatments or procedures. The goal is to create a practical tool that can be used by hospitals and doctors to better evaluate and improve gastric cancer surgery outcomes.

详细描述

Gastric cancer remains a leading cause of cancer-related mortality worldwide, with significant variation in surgical outcomes across healthcare institutions. Current outcome reporting lacks adequate risk adjustment, making it difficult to distinguish between differences in patient populations versus actual care quality. This limitation hampers quality improvement efforts and evidence-based decision making.

This retrospective cohort study addresses this gap by developing the Surgical Assessment and Healthcare (SAH) Index, a comprehensive risk-adjustment tool specifically designed for gastric cancer surgery evaluation. The study leverages a unique dataset combining clinical, pathological, and molecular characteristics of 780 consecutive gastric cancer patients who underwent surgical resection in 2019.

The SAH Index development follows established risk prediction modeling methodology. Univariate analysis will identify potential predictors across four domains: clinical factors (demographics, comorbidities, performance status), surgical factors (procedure type, surgeon experience), pathological factors (tumor stage, grade, Lauren classification), and molecular factors (HER2, microsatellite instability, mismatch repair status, PD-L1 expression). Multivariable Cox regression and logistic regression models will be constructed for survival and morbidity outcomes, respectively.

Model development includes variable selection using backward elimination, assessment of multicollinearity, and evaluation of interaction terms. Internal validation will employ bootstrap resampling techniques to assess model stability and prevent overfitting. The final SAH Index will stratify patients into distinct risk categories with corresponding risk-adjusted outcome predictions.

Performance metrics include discrimination (C-statistic), calibration (Hosmer-Lemeshow test), and clinical utility assessment. The index will be validated against existing risk stratification tools and tested for its ability to detect outcome differences between healthcare providers after risk adjustment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者
否

入选标准

  • •Age: 18 years and older Diagnosis: Histologically confirmed gastric adenocarcinoma Treatment: Underwent surgical resection in 2019 Data availability: Complete clinical, pathological, and molecular marker data Follow-up: Minimum 6 months post-operative follow-up data available

排除标准

  • •Histology: Non-adenocarcinoma gastric tumors Surgery type: Emergency surgery or palliative procedures only Data quality: Missing essential clinical, pathological, or molecular data required for SAH Index development Follow-up: Lost to follow-up within 30 days post-surgery

结局指标

主要结局

Development of SAH Index for Risk-Adjusted Gastric Cancer Surgical Evaluation

时间窗: 5 years post-surgery

Development and internal validation of the Surgical Assessment and Healthcare (SAH) Index incorporating clinical, pathological, and molecular factors to predict surgical outcomes in gastric cancer patients. Performance assessed by discrimination (C-statistic), calibration (Hosmer-Lemeshow test), and risk stratification accuracy.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

BIRENDRA KUMAR SAH

RESEARCH SCIENTIST

Ruijin Hospital

研究点 (1)

Loading locations...

相似试验